ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares


You May Also Like

Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), ...

Aptevo Therapeutics Reports First Quarter 2017 Financial Results

Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK ...